Mariapia Vietri

Dr. Mariapia Vietri

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MVMariapia Vietri
Mariapia Vietri
MMMaria Rosaria Miranda
Maria Rosaria Miranda
Giuseppina AmodioGiuseppina Amodio
Giuseppina Amodio
TCTania Ciaglia
Tania Ciaglia
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
OMOrnella Moltedo
Ornella Moltedo
Lysosomal dysfunction and endoplasmic reticulum (ER) stress play essential roles in cancer cell survival, growth, and stress adaptation. Among the various stressors in the tumor microenvironment, oxidative stress (OS) is a central driver that exacerbates both lysosomal and ER dysfunction. In healthy cells, the ER manages protein folding and redox balance, while lysosomes regulate autophagy and degradation. Cancer cells, however, are frequently exposed to elevated levels of reactive oxygen species (ROS), which disrupt protein folding in the ER and damage lysosomal membranes and enzymes, promoting dysfunction. Persistent OS activates the unfolded protein response (UPR) and contributes to lysosomal membrane permeabilization (LMP), leading to pro-survival autophagy or cell death depending on the context and on the modulation of pathways like PERK, IRE1, and ATF6. Cancer cells exploit these pathways by enhancing their tolerance to OS and shifting UPR signaling toward survival. Moreover, lysosomal impairment due to ROS accumulation compromises autophagy, resulting in the buildup of damaged organelles and further amplifying oxidative damage. This vicious cycle of ROS-induced ER stress and lysosomal dysfunction contributes to tumor progression, therapy resistance, and metabolic adaptation. Thus, targeting lysosomal and ER stress responses offers potential as cancer therapy, particularly in increasing oxidative stress and promoting apoptosis. This review explores the interconnected roles of lysosomal dysfunction, ER stress, and OS in cancer, focusing on the mechanisms driving their crosstalk and its implications for tumor progression and therapeutic resistance.

23 December 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
TCTania Ciaglia
Tania Ciaglia
MMMaria Rosaria Miranda
Maria Rosaria Miranda
Simone Di MiccoSimone Di Micco
Simone Di Micco
MVMariapia Vietri
Mariapia Vietri
GSGerardina Smaldone
Gerardina Smaldone
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
Based on the established neuroprotective properties of indole-based compounds and their significant potential as multi-targeted therapeutic agents, a series of synthetic indole–phenolic compounds was evaluated as multifunctional neuroprotectors. Each compound demonstrated metal-chelating properties, particularly in sequestering copper ions, with quantitative analysis revealing approximately 40% chelating activity across all the compounds. In cellular models, these hybrid compounds exhibited strong antioxidant and cytoprotective effects, countering reactive oxygen species (ROS) generated by the Aβ(25–35) peptide and its oxidative byproduct, hydrogen peroxide, as demonstrated by quantitative analysis showing on average a 25% increase in cell viability and a reduction in ROS levels to basal states. Further analysis using thioflavin T fluorescence assays, circular dichroism, and computational studies indicated that the synthesized derivatives effectively promoted the self-disaggregation of the Aβ(25–35) fragment. Taken together, these findings suggest a unique profile of neuroprotective actions for indole–phenolic derivatives, combining chelating, antioxidant, and anti-aggregation properties, which position them as promising compounds for the development of multifunctional agents in Alzheimer’s disease therapy. The methods used provide reliable in vitro data, although further in vivo validation and assessment of blood–brain barrier penetration are needed to confirm therapeutic efficacy and safety.

9 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
FMFrancesca Di Matteo
Francesca Di Matteo
MVMariapia Vietri
Mariapia Vietri
DSD’Alessio Simone
D’Alessio Simone
TCTania Ciaglia
Tania Ciaglia
EVErica Federica Vestuto
Erica Federica Vestuto
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
Background/Objectives: Cathepsins, lysosomal proteases crucial for neuronal proteostasis, mediate the clearance of misfolded and aggregated proteins. Their dysregulation is implicated in neurodegenerative and neuropsychiatric disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. These conditions are characterized by toxic protein accumulation and impaired clearance, which exacerbate cellular stress responses, including the unfolded protein response (UPR), oxidative damage, and mitochondrial dysfunction. This review aims to summarize current knowledge on cathepsin roles in these pathways and assess their therapeutic potential. Methods: A comprehensive literature review was conducted, focusing on recent in vitro and in vivo studies investigating cathepsin function, inhibition, and modulation. Mechanistic insights and pharmacological approaches targeting cathepsins were analyzed, with attention to challenges in translating preclinical findings to clinical settings. Results: Cathepsins demonstrate a dual role: their proteolytic activity supports neuronal health by degrading toxic aggregates, but altered or insufficient activity may worsen proteotoxic stress. Studies reveal that cathepsins regulate autophagy, apoptosis, and neuroinflammation both intracellularly and extracellularly. Despite promising mechanistic data, clinical translation is hindered by issues such as poor inhibitor selectivity, limited brain penetration, and variability across preclinical models. Conclusions: Targeting cathepsins presents a promising strategy for treating neurodegenerative and neuropsychiatric disorders, but significant challenges remain. Future research should focus on improving drug specificity and delivery, and on developing standardized models to better predict clinical outcomes.

Verified
Journal Article
Open access
PDF file
PMPietro Mazzeo
Pietro Mazzeo
MVMariapia Vietri
Mariapia Vietri
NTNicola Tecce
Nicola Tecce
ADAlessia Delizia
Alessia Delizia
VRValentina Remondelli
Valentina Remondelli
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
Sodium–glucose cotransporter-2 (SGLT2) inhibitors, initially developed as antidiabetic agents, have recently gained attention for their potential role in modulating processes relevant to Alzheimer’s disease (AD). Preclinical studies suggest that they may influence key mechanisms involved in AD. However, available clinical studies, mainly retrospective and focused on diabetic populations, provide insufficient clarity on whether these effects extend to broader, non-diabetic groups. The heterogeneity of neurodegenerative diseases, which differ in inflammatory and proteotoxic mechanisms, further highlights the need for disease-specific investigations. This review examines mechanistic pathways through which SGLT2 inhibition may influence AD progression and evaluates current clinical evidence, aiming to identify key knowledge gaps and guide future research. This review summarises the latest evidence from the literature, focusing on preclinical experiments, translational studies and early clinical observations. The search focused on pathways related to microglial and astrocytic activation, oxidative stress, metabolic remodeling, neuronal survival, and amyloid and tau dynamics. Accumulating data indicate that SGLT2 inhibitors exert multifaceted actions relevant to AD pathology, including reduced neuroinflammation and oxidative stress, improved mitochondrial and insulin signaling, as well as decreased amyloid deposition and tau hyperphosphorylation. Additionally, SGLT2 inhibition may improve cerebrovascular perfusion and blood–brain barrier stability, potentially supporting cognitive function. Nonetheless, major challenges remain, including variable blood–brain barrier permeability and heterogeneous experimental responses. SGLT2 inhibitors represent a promising pleiotropic class of compounds with potential disease-modifying effects in AD. Their capacity to target metabolic, inflammatory, and proteotoxic pathways makes them attractive candidates for neurodegenerative therapy. Further studies are required to clarify biochemical pathways and validate clinical efficacy.

26 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
MVMariapia Vietri
Mariapia Vietri
ENEnza Napolitano
Enza Napolitano
MMMaria Rosaria Miranda
Maria Rosaria Miranda
Carmen MarinoCarmen Marino
Carmen Marino
SMSimona Musella
Simona Musella
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
Ferroptosis has emerged as a critical mechanism linking iron dysregulation, oxidative stress, and neurodegeneration in amyloid-associated pathologies. Building on our previous work, which identified compound 20 as a promising antioxidant and neuroprotective agent, the present study investigates the molecular mechanisms underlying its protective activity against amyloid-induced ferroptosis in human neuroblastoma SH-SY5Y cells exposed to Aβ(25–35). Compound 20 (3-(((4-hydroxybenzyl)(methyl)amino)methyl)-1-methyl-N-(2-(piperazin-1-yl)ethyl)-1H-indole-5-carboxamide) markedly counteracted Aβ(25–35)-induced ferroptotic damage by restoring intracellular glutathione levels, depleting the labile iron pool, and suppressing lipid peroxidation. In parallel, the compound significantly rescued mitochondrial membrane potential and attenuated endoplasmic reticulum (ER) expansion associated with ER stress, thereby preserving cellular homeostasis under oxidative challenge. These protective effects were further corroborated by real-time PCR analysis, which revealed the modulation of key genes involved in the oxidative stress response, endoplasmic reticulum stress, and inflammatory pathways. To gain a systems-level insight into these mechanisms, untargeted 1H-NMR metabolomic profiling was performed. This analysis confirmed the activation of antioxidant pathways and disclosed a significant modulation of energy metabolism and GABA-related pathways, both of which are closely linked to redox balance and neuronal resilience. Overall, these findings demonstrate that compound 20 drives metabolic reprogramming that orchestrates its multifactorial protective effect against Aβ(25–35)-induced ferroptosis by coordinating antioxidant defense, iron homeostasis, and ER stress mitigation.

8 November 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
MVMariapia Vietri
Mariapia Vietri
ADAlessia Delizia
Alessia Delizia
TCTania Ciaglia
Tania Ciaglia
Carla SardoCarla Sardo
Carla Sardo
SMSimona Musella
Simona Musella
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
Background/Objectives: Cathepsins, a family of lysosomal proteases essential for cellular proteostasis, have functions that extend beyond canonical degradation and recycling processes. Their dysregulation has been strongly associated with tumorigenesis, where cathepsins promote multiple hallmarks of cancer, including extracellular matrix remodeling, invasion, proliferation, and inflammation. Both intracellular and extracellular cathepsin activities contribute to tumor microenvironment shaping and influence the response to anticancer therapies, particularly chemoresistance. This review aims to summarize current knowledge on the biochemical regulation of cathepsins in cancer and evaluate their potential as therapeutic targets. Methods: A comprehensive literature analysis was conducted, focusing on recent in vitro, in vivo, and translational studies examining cathepsins’ functions, substrate specificity, biochemical pathways, and pharmacological modulations. Special attention was given to research addressing inhibitor development, therapeutic targeting strategies, and challenges associated with selectivity, delivery, and model variability. Results: Evidence indicates that cathepsins exhibit a multifaceted role in cancer. Extracellular cathepsins facilitate matrix degradation and metastatic dissemination, while intracellular cathepsins regulate key signaling networks that promote tumor cell survival, proliferation, autophagy, and inflammatory responses. Furthermore, cathepsins contribute to tumor microenvironment remodelling and modulate sensitivity to chemotherapy, supporting multiple mechanisms of therapy resistance. Although preclinical studies highlight promising therapeutic opportunities, significant limitations persist, including poor inhibitor specificity, challenges in drug delivery, compensatory activation among cathepsin isoforms that may sustain overlapping proteolytic functions, and heterogeneous responses across tumor types. Conclusions: Targeting cathepsins is an emerging strategy in oncology, but effective translation requires a deeper understanding of the complex biochemical networks they regulate. Given their broad and interconnected roles, clarifying these pathways is essential to anticipate global effects and potential toxicities. Future work should therefore define this molecular hub and develop approaches that ensure selective and safe cathepsin modulation.